RxDoctor Payments Data

Mary Cheng

Optometrist · Rosemead, CANPI 1477582849

Payments from drug & device makers

$4,963in general payments, 2019–2025

Across 220 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$3K
  • Alcon$782
  • Bausch & Lomb Americas Inc.$480
  • Oyster Point Pharma, Inc.$378
  • Novartis$237
  • AbbVie$180
  • plus $228 from 6 others

What the payments were for

  • Food & beverage$4,963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,963 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$89,162
Medicare patients
286
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf462$339,099
SimbrinzaBrinzolamide/Brimonidine Tart641$126,582
CequaCyclosporine197$110,700
RocklatanNetarsudil Mesylat/Latanoprost142$48,585
RestasisCyclosporine50$30,795
XiidraLifitegrast32$27,815
ProlensaBromfenac Sodium71$23,062
LumiganBimatoprost68$19,261
Cyclosporine49$15,054
VyzultaLatanoprostene Bunod40$12,177
BesivanceBesifloxacin Hcl54$11,909
TyrvayaVarenicline Tartrate17$10,508
Bromfenac Sodium25$5,110
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat119$3,041
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$2,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$480$379,091534 claims
AlconSimbrinza$782$126,582641 claims
Sun Pharmaceutical Industries Inc.Cequa$2,678$110,700197 claims
AbbVieRestasis, Lumigan$180$50,056118 claims
Aerie Pharmaceuticals, Inc.Rocklatan$53$48,585142 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance$23$34,971125 claims
Oyster Point Pharma, Inc.Tyrvaya$378$10,50817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.

Other optometrist in Rosemead

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →